Log in
Enquire now
‌

US Patent 10912828 Anti-TIM-3 antibodies and methods of use thereof

Patent 10912828 was granted and assigned to Agenus on February, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Agenus
Agenus
Current Assignee
Agenus
Agenus
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10912828
Date of Patent
February 9, 2021
Patent Application Number
16806299
Date Filed
March 2, 2020
Patent Citations
‌
US Patent 10639368 Anti-TIM-3 antibodies and methods of use thereof
Patent Citations Received
‌
US Patent 12011481 Anti-TIM-3 antibodies and methods of use thereof
0
‌
US Patent 11839653 Anti-TIM-3 antibodies and methods of use thereof
0
Patent Primary Examiner
‌
Lynn A Bristol
Patent abstract

The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10912828 Anti-TIM-3 antibodies and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.